EU/3/16/1791

Table of contents

About

On 18 November 2016, orphan designation (EU/3/16/1791) was granted by the European Commission to Dr Ulrich Granzer, Germany, for a vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions (also known as DPX-Survivac) for the treatment of ovarian cancer.

The sponsorship was transferred to FGK Representative Service GmbH, Germany, in June 2020.

Key facts

Active substance
vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions
Disease / condition
Treatment of ovarian cancer
Date of first decision
18/11/2016
Outcome
Positive
EU designation number
EU/3/16/1791

Sponsor's contact details

Medpace Finland Oy
Karjalankatu 2
00520 Helsinki
Helsinki-Uusimaa
Finland
Tel: +1 20 1322 9148
E-mail: z.toor@nspharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating